MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Roivant Sciences Ltd

Suletud

SektorTervishoid

11.35 -1.65

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.28

Max

11.55

Põhinäitajad

By Trading Economics

Sissetulek

-278M

-252M

Müük

-1.4M

7.6M

Aktsiakasum

-0.29

Kasumimarginaal

-3,333.884

Töötajad

750

EBITDA

-9.2M

-284M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+30.51% upside

Turustatistika

By TradingEconomics

Turukapital

-292M

7.3B

Eelmine avamishind

13

Eelmine sulgemishind

11.35

Uudiste sentiment

By Acuity

50%

50%

174 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Roivant Sciences Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. juuli 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

FCC Approves U.S. Cellular Sale to T-Mobile

11. juuli 2025, 17:28 UTC

Suurimad hinnamuutused turgudel

SharpLink Gaming Gains on Ethereum Purchase

11. juuli 2025, 16:57 UTC

Tulu

BASF Cuts Outlook on Global Economy Uncertainty

11. juuli 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11. juuli 2025, 19:46 UTC

Omandamised, ülevõtmised, äriostud

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11. juuli 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11. juuli 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11. juuli 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11. juuli 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11. juuli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11. juuli 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11. juuli 2025, 16:42 UTC

Tulu

BASF Cuts Outlook on Global Economic Uncertainty

11. juuli 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11. juuli 2025, 16:05 UTC

Tulu

BASF Will Publish Half-Year Results on July 30

11. juuli 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11. juuli 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11. juuli 2025, 16:03 UTC

Tulu

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11. juuli 2025, 16:02 UTC

Tulu

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11. juuli 2025, 16:01 UTC

Tulu

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11. juuli 2025, 16:00 UTC

Tulu

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11. juuli 2025, 15:59 UTC

Tulu

BASF Cuts 2025 Earnings View

11. juuli 2025, 15:58 UTC

Tulu

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11. juuli 2025, 15:57 UTC

Tulu

BASF 2Q EBIT Before Special Items EUR810M

11. juuli 2025, 15:54 UTC

Tulu

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11. juuli 2025, 15:54 UTC

Tulu

BASF 2Q Sales Fell 2.1% on Year

11. juuli 2025, 15:53 UTC

Tulu

BASF 2Q Sales EUR15.77B

11. juuli 2025, 15:52 UTC

Tulu

BASF: This Was in Line With Consensus Estimates

11. juuli 2025, 15:52 UTC

Tulu

BASF 2Q Ebitda Before Special Items EUR1.77B

11. juuli 2025, 15:49 UTC

Tulu

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11. juuli 2025, 15:41 UTC

Market Talk

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Roivant Sciences Ltd Prognoos

Hinnasiht

By TipRanks

30.51% tõus

12 kuu keskmine prognoos

Keskmine 15.1 USD  30.51%

Kõrge 19 USD

Madal 11.5 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Roivant Sciences Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

7

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

11 / 11.18Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

174 / 376 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.